ESC 365 - Risk stratification in PAH: are any of our patients really "low risk"?

ESC Premium Access

Risk stratification in PAH: are any of our patients really "low risk"?

Session: Can you achieve more for your pulmonary arterial hypertension (PAH) patients? An expert review of key recent data with initial combination therapy

Topic: Chronic pulmonary hypertension

Speaker: Professor I. Lang (Vienna, AT)

Sponsored by GSK

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Irene Marthe Lang

Medical University of Vienna, Vienna (Austria)

33 presentations

5 followers

4 more presentations in this session

Introduction - Can you achieve more for your pulmonary arterial hypertension (PAH) patients? An expert review of key recent data with initial combination therapy.

Speaker: Professor I. Lang (Vienna, AT)

The importance of reducing hospitalisations in PAH.

Speaker: Professor J. Vachiery (Brussels, BE)

Can your connective tissue disease-associated PAH patients achieve similar outcomes to your idiopathic PAH patients?

Speaker: Doctor J. Coghlan (London, GB)

Q&A - Can you achieve more for your PAH patients? An expert review of key recent data with initial combination therapy.

Speaker: Professor I. Lang (Vienna, AT)

Access the full session

Can you achieve more for your pulmonary arterial hypertension (PAH) patients? An expert review of key recent data with initial combination therapy

Speakers: Professor I. Lang, Professor I. Lang, Professor J. Vachiery, Doctor J. Coghlan, Professor I. Lang

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources